Articles, guides, and regulatory updates from our community.
New research explores retatrutide's role in CKM syndrome, showing significant weight loss, glycemic control, and cardiorenal benefits in Phase 2 trials.
By Peptide Association Research Team
New research on retatrutide shows promising weight loss and metabolic results. Learn what the 2026 clinical review found about this triple hormone receptor agonist.
By Peptide Association Research Team
New research on retatrutide, a triple-agonist peptide therapy, demonstrates significant benefits for type 2 diabetes and obesity management in clinical studies.
By Peptide Association Research Team